Understanding rejection mechanisms and subsequently improving immunosuppression strategies after liver transplantation is still a goal for transplant specialists. All the efforts aim to find a balance between efficacy in preventing rejection and safety with the minimization of side effects. While the use of standard protocols is an easy choice, there is a growing interest in a more complex, personalized approach. This webinar will focus on alloreactive T lymphocytes which are the primary mediators of rejection, early and long-term immunosuppression regimens, discussing different approaches and perspectives for future research.
Learn how to track donor-reactive T cells
Discuss the use of induction therapy, indication, benefits and side effects
Discuss immunosuppression minimization and the use of mTOR inhibitors
Tracking the alloresponse in human transplant recipients (Megan Sykes)
Is induction therapy justified in all LT recipients? (Varuna Aluvihare)
CNI reduced exposure/withdrawal in maintenance therapy: the role of mTOR inhibitors (Faouzi Saliba)
Q&A moderated by Geoffrey McCaughan and Eleonora De Martin
Dr Sykes is the director, Columbia Center for Translational Immunology, the director of Research, Transplant Initiative and the director of Bone Marrow Transplantation Research, Division of Hematology/Oncology. She is Professor of Microbiology and Immunology and Surgical Sciences (in Surgery) and Michael J. Friedlander Professor of Medicine. She is a Past President of the International Xenotransplantation Association, served as Vice President of TTS, has repeatedly served on TTS Council and is a member of the Institute of Medicine of the National Academies and of the Association of American Physicians. She has received many honors and awards, including the 2018 Medawar Prize. Dr. Sykes’ own laboratory program currently includes major projects in the area of xenograft tolerance induction in humanized mouse models; unique humanized mouse models for the analysis and treatment of autoimmune diseases; studies of lymphocyte turnover, chimerism and T cell trafficking in patients receiving intestinal and liver transplants; tracking of alloreactive T cells in human transplant recipients; and both pre-clinical and clinical studies of non-myeloablative hematopoietic cell transplantation for the induction of allograft tolerance.
Dr Aluvihare is Transplant Hepatology and Governance Lead at the Institute of Liver Studies, King’s College Hospital, and Chair of the British Liver Transplant Group. He qualified at the Royal Free Hospital and completed his professional training at Addenbrooke’s Hospital, Cambridge. He undertook MRC funded Training (PhD) and Clinician Scientist fellowships in Immunology/Molecular Biology at the worldrenowned MRC Laboratory of Molecular Biology, University of Cambridge. He was awarded a 5-year HEFCE Senior Lecturer Fellowship and an ROTRF grant in transplantation research at King’s College Hospital. He is a member of the UK Liver Transplant Advisory Group, Hepatology representative on the National Multivisceral Transplantation Review Group, Transplant Hepatology representative on the British TransplantSociety Council and a member of the Editorial Board for Liver Transplantation.
Dr Saliba is an Associate Professor in Hepatology and Gastro-Enterology and at the University of Paris-Saclay, France and is in charge of the Intensive Care and Endoscopy Unit at the Hepato-Biliary Centre and Liver Transplant Unit at Paul Brousse Hospital (Assistance Publique-Hôpitaux de Paris). He is a consultant in Hepatology and Gastro-Enterology and has been working for over 30 years in the management of patients affected with hepato-biliary diseases and liver transplantation. He has been in the Administrative Board of Paul Brousse-Bicètre-Béclère Hospital group. He’s a member of several national and international societies. Dr Saliba is on head of a clinical research unit at Paul Brousse Hospital. He has conducted, coordinated, and participated in several international and national clinical trials in the fields of hepatology, transplantation, artificial and bioartificial liver support, immunology, and infectious diseases. He has published over 220 original papers in official and peer-reviewed journals, in addition to many other journal articles, book chapters and textbooks.
Dr McCaughan is currently the AW Morrow Professor of Medicine (Gastroenterology and Hepatology) at the Royal Prince Alfred Hospital and the University of Sydney. He is also Director of Transplant Hepatology, the GE/Liver Diagnostic Laboratory, and the Liver Immunobiology Research Laboratory Centenary Research Institute for Cancer and Cell Biology. His primary clinical interests are liver transplantation, viral hepatitis and autoimmune hepatitis.
Dr De Martin is a transplant hepatologist at Centre Hépato-Biliaire, Paul Brousse Hospital in France. She is the Vice-Chair of ILTS Vanguard Committee and topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group. Her fields of interest include liver transplantation, autoimmune hepatitis in particular severe acute and fulminant forms and hepatic toxicity of immunotherapy for metastatic cancer.